How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.
作者信息
Chahine Zena, Meirson Tomer, Gilboa Shai, Mohyuddin Ghulam Rehman
机构信息
Division of Hematology, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel.
出版信息
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf122.
Abstract
摘要
Zotero 插件